ArticleClinical and experimental medicine2026
Identification of key programmed cell death genes-necroptosis-related genes in systemic lupus erythematosus.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with challenging early diagnosis. Aberrant programmed cell death (PCD) is critical in SLE pathogenesis. This study aimed to identify key PCD genes for SLE diagnosis and disease activity assessment. Integrated bioinformatics analysis was conducted on three whole-blood transcriptomic datasets (GSE65391, GSE110174, GSE154851) from GEO. Machine learning algorithms (LASSO, SVM-RFE) identified hub genes across 18 PCD types. ssGSEA and logistic regression determined the predominant PCD pathway. Immune infiltration and correlation analyses evaluated clinical relevance. Necroptosis was identified as the most discriminative PCD pathway (AUC = 0.950, 95% CI: 0.921–0.979). Seven necroptosis-related genes (STAT1, STAT2, ZBP1, CASP1, TNFSF10, RIPK3, IL1B) were validated as key diagnostic biomarkers. A multivariate logistic regression model demonstrated robust performance across training and external validation cohorts, confirmed by internal validation (20 SLE patients and 16 healthy controls). The seven genes correlated significantly with dysregulated immune cells and were positively associated with SLEDAI, dsDNA levels, and neutrophil percentages. Necroptosis is a critical PCD pathway in SLE. The seven necroptosis-related genes represent promising diagnostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.